Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Cuts Could Come From HHS In 2019 With No IPAB In Sight

This article was originally published in The Pink Sheet Daily

Executive Summary

There is a 'fair' likelihood that the Independent Payment Advisory Board will be called on to propose spending cuts to Medicare, effective in 2019, the CMS chief actuary says. And if there is no IPAB in existence, HHS will assume responsibility.

You may also be interested in...



Medicare Spending Growth Won't Trigger IPAB Cost Reduction Plan

Threat of Independent Payment Advisory Board action to lower drug spending in Medicare alleviated for another year. Estimated spending growth in the program does not reach targets that would prompt cuts.

Trump’s ACA Repeal: What’s In It For Biopharma?

Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.

Trump’s ACA Repeal: What’s In It For Biopharma?

Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079545

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel